Form 4: Evoke Pharma CFO Mark Kowieski Reports Transaction in Company Stock
SEC Form 4 Filing
Mark Kowieski, CFO of Evoke Pharma, reports the acquisition and disposal of company stock on March 20, 2025.
Summary
- On March 20, 2025, Mark Kowieski, the Chief Financial Officer of Evoke Pharma, engaged in transactions involving the company's common stock.
- Kowieski acquired 4,500 shares of common stock at a price of $3.214 per share.
- Following the reported transactions, Kowieski beneficially owns 4,916 shares of Evoke Pharma.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions by an insider. The acquisition could be seen as slightly positive, but without more context, it's difficult to gauge the overall impact.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may be interested in the CFO's stock transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | Date of stock transaction (acquisition and disposal). |
| 03/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Evoke Pharma, EVOK, Form 4, SEC Filing, Insider Trading, Mark Kowieski, CFO, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.